Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
MYO1A Antibody, BBMI Antibody, BBM-I Antibody, DFNA48 Antibody, MIHC Antibody, MYHL Antibody, Myosin I heavy chain Antibody, Brush border myosin I Antibody, Myosin IA Antibody, Unconventional myosin-Ia Antibody
MYO1A is a member of the myosin superfamily. The protein represents an unconventional myosin; it should not be confused with the conventional skeletal muscle myosin-1 (MYH1). Unconventional myosins contain the basic domains characteristic of conventional myosins and are further distinguished from class members by their tail domains. They function as actin-based molecular motors. Mutations in this gene have been associated with autosomal dominant deafness.
Western blot of MYO1A antibody (Center S291) in Jurkat cell line lysates (35 ug/lane). MYO1A (arrow) was detected using the purified antibody.
MYO1A Antibody (Center S291) flow cytometry of Jurkat cells (bottom histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.